博拓生物9月15日获融资买入1943.01万元，融资余额2.00亿元

Core Viewpoint - 博拓生物's stock performance shows a slight decline, with significant financing activity indicating high investor interest despite recent revenue and profit decreases [1][2]. Financing Summary - On September 15, 博拓生物 experienced a financing buy-in of 19.43 million yuan, with a net buy of 4.59 million yuan after 14.84 million yuan in repayments [1]. - The total financing balance reached 200 million yuan, accounting for 3.15% of the circulating market value, which is above the 90th percentile of the past year [1]. - No short selling activity was recorded on September 15, with a short balance of 0 yuan, also indicating a high position relative to historical data [1]. Company Performance Summary - As of June 30, 博拓生物 reported a revenue of 203 million yuan for the first half of 2025, reflecting a year-on-year decrease of 23.91% [1]. - The net profit attributable to shareholders was 12.40 million yuan, down 82.82% compared to the previous year [1]. - The number of shareholders decreased by 10.13% to 5,583, while the average circulating shares per person increased by 55.77% to 26,747 shares [1]. Dividend Summary - 博拓生物 has distributed a total of 798 million yuan in dividends since its A-share listing, with 478 million yuan paid out over the last three years [2]. Institutional Holdings Summary - As of June 30, 2025, the sixth largest circulating shareholder is 广发价值核心混合A, holding 4.236 million shares, an increase of 1.5021 million shares from the previous period [2].